Drug Profile
ABT 925
Alternative Names: A-437203; ABT-925; BSF-201640; DTA 201; LU 201640Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Antipsychotics; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 09 Nov 2007 Phase II trials are ongoing
- 28 Mar 2001 Phase-II clinical trials for Schizophrenia (Unknown route)
- 12 Nov 1999 Phase-I clinical trials for Schizophrenia (Unknown route)